Journal of Clinical Oncology
Articles in this Issue
Exploring two decades of cancer trends in adolescents and young adults: Insights from a resource-restricted country.
11058 Background: Over 40% of the Jordan population are adolescents and young adults (AYA), aged 15-39 years. Cancer diagnoses in this age group have dist...
PD-L1 expression level in a large cohort from an Indian center.
e14632 Background: PD-L1, or Programmed Death-Ligand 1, is a protein expressed on the surface of various cells, including tumor cells. PD-L1 is a key biom...
Sex differences in survival of anal melanoma: An analysis of the United States National Cancer Database.
e21607 Background: Mucosal melanoma is a rare, more aggressive subtype of melanoma, accounting for < 2% of all melanomas and associated with a poorer p...
Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia.
e18542 Background: In patients with acute myeloid leukemia (AML), infections are a major cause of morbidity and mortality. Fungal, bacterial, and viral pr...
Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.
4597 Background: In the ENVISION pivotal phase 3 study (NCT05243550) patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-N...
Impact of the COVID-19 pandemic on inpatient outcomes for cancer patients in the United States.
e23293 Background: The COVID-19 pandemic significantly disrupted cancer care in the United States, yet few studies have comprehensively examined its impac...
MUC5AC profiling as a biomarker for predicting post-recurrence outcomes and guiding precision therapy in pancreatic ductal adenocarcinoma (PDA).
e16374 Background: Our previous work on resected PDA patients did not fully explore the impact of MUC5AC profiling—including extracellular MUC5AC (EC-M) a...
Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM).
7535 Background: In patients with NDMM, therapy after ASCT aims to deepen remission and prolong survival. Although lenalidomide (R) monotherapy after ASCT...
CCR8 positive Tregs and their correlation with immunotherapy response in advanced non-small cell lung cancer (NSCLC).
2635 Background: Regulatory T cells (Tregs) expressing the chemokine receptor CCR8 are pivotal modulators of the tumor immune microenvironment. CCR8 has r...
Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC).
555 Background: Emerging evidence from prospective studies underscores the prognostic potential of ctDNA to inform risk stratification and clinical decisi...
Impact and disparities of COVID-19 on hematological malignancies: A database study focused on hospitalized patients in North America.
e23322 Background: The COVID-19 pandemic has presented significant risks to the hematological malignancy patients worldwide, including elevated hospitaliz...
Comorbidity burden and risk factors (RFs) for peripheral neuropathy (PN) and their prevalence in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Combined results of 2 systematic literature reviews (SLRs) and a meta-analysis.
e23313 Background: Despite advances in the treatment options for la/mUC, concerns remain about the occurrence of adverse events, such as PN, in daily prac...
Retrospective, observational study to describe the clinical characteristics, management, and outcomes of bispecific anti-gprc5d antibody in patients with relapsed refractory multiple myeloma treated outside clinical trials in Spain.
e19542 Background: Talquetamab (TAL), a pioneering bispecific antibody targeting GPRC5D, received approval in Europe in August 2023. Before this, in Novem...
Possibility of using the combination of everolimus/sorafenib medications in the treatment of children and adolescents with refractory osteosarcoma and Ewing sarcoma.
e23513 Background: Treatment outcomes for children and adolescents with refractory osteosarcoma and Ewing's sarcoma remain unsatisfactory. According to th...
A multi-center study on the role of ACSL4 in invasion and metastasis of hepatocellular carcinoma.
e16213 Background: Hepatocellular carcinoma (HCC) has an easy recurrence and poor prognosis. Tumor invasive front (TIF) is the source of tumor recurrence...
Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor <i>ADRB2</i> in triple negative breast cancer (TNBC).
1107 Background: Chronic stress-mediated β2-adrenergic receptor (β2-AR) signaling promotes tumor growth via immunosuppression in the tumor microenvironmen...
Cognitive outcomes following proton vs. photon radiotherapy for CNS non-germinomatous germ cell tumors: A Children’s Oncology Group study.
10016 Background: The Children’s Oncology Group (COG) study ACNS1123 (stratum 1) treated children with localized non-germinomatous germ cell tumors (NGGCT...
Clinical, environmental, genetic, and genomic profile of patients with rapid progression to metastatic castration resistant prostate cancer (mCRPC).
e17053 Background: Patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) that develop rapid progression to castration resistance follow...
Updated analyses from a global meta-analysis in metastatic uveal melanoma (mUM) to determine progression free and overall survival benchmarks by line of therapy: An international rare cancers initiative (IRCI) ocular melanoma study.
9539 Background: PUMMA is an individual trial patient level meta-analysis that established survival and prognostic benchmarks in metastatic uveal melanoma...
Association between frailty and clinical outcomes in older adults with early breast cancer: Results from the Hurria Older Patients (HOPE) study.
11040 Background: Older adults with early breast cancer are a heterogenous population with varying physiologic and functional age. Pretreatment frailty ma...
Clinico-genomic characteristics of clinical trial participation and its impact on clinical outcome in metastatic NSCLC: A nationwide database analysis in Japan.
8626 Background: The clinico-genomic factors influencing clinical trial participation and their impact on clinical outcomes remain unclear. We investigate...
Tislelizumab and sitravatinib as adjuvant therapy for hepatocellular carcinoma patients at high risk of recurrence following surgical resection: A multi-center, non-randomized, open-label phase 2 study.
e16282 Background: Hepatocellular carcinoma (HCC) has a high risk of recurrence after resection. The IMbrave 050 trial suggested that adjuvant atezolizuma...
Is circulating tumor DNA the best surveillance tool for detecting post-adjuvant relapse in stage I-III breast cancer patients?
e12505 Background: Despite advances made in breast cancer management, sensitive methods to detect relapse are limited to clinical examination and imaging....
Early treatment ctDNA dynamics to predict response to chemotherapy in patients with metastatic pancreatic cancer: A prospective, observational pilot study.
4158 Background: Assessment of chemotherapy response using imaging has limitations in metastatic pancreatic cancer whereas circulating tumor DNA (ctDNA) m...
Safety and efficacy of radiotherapy combined with anlotinib in locally advanced non-small cell lung cancer patients intolerant to concurrent chemoradiotherapy: Preliminary result of a phase II clinical trial.
8043 Background: Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with unresectable locally advanced non-small cell lung cancer...